Your browser doesn't support javascript.
loading
RPL41 sensitizes retinoblastoma cells to chemotherapeutic drugs via ATF4 degradation.
Geng, Wen; Ren, Jiaxu; Shi, Huimin; Qin, Feng; Xu, Xiaohe; Xiao, Sheng; Jiao, Yisheng; Wang, Aiyuan.
Afiliación
  • Geng W; Department of Ophthalmology, Shengjing Hospital of China Medical University, Shengyang, Liaoning, China.
  • Ren J; Department of Ophthalmology, Shengjing Hospital of China Medical University, Shengyang, Liaoning, China.
  • Shi H; Department of Ophthalmology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
  • Qin F; Department of Ophthamology, Shenyang Aier Eye Hospital, Shenyang, Liaoning, China.
  • Xu X; Department of Ophthalmology, Shengjing Hospital of China Medical University, Shengyang, Liaoning, China.
  • Xiao S; Department of Pathology, Brigham and Women's Hospital of Harvard Medical School, Boston, Massachusetts.
  • Jiao Y; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shengyang, Liaoning, China.
  • Wang A; Department of Ophthalmology, Shengjing Hospital of China Medical University, Shengyang, Liaoning, China.
J Cell Physiol ; 236(3): 2214-2225, 2021 03.
Article en En | MEDLINE | ID: mdl-32783256
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Retinoblastoma / Proteínas Ribosómicas / Factor de Transcripción Activador 4 / Proteolisis / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Cell Physiol Año: 2021 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Retinoblastoma / Proteínas Ribosómicas / Factor de Transcripción Activador 4 / Proteolisis / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Cell Physiol Año: 2021 Tipo del documento: Article País de afiliación: China